Bioelectricity Commercialization Stack
Jonny Miller@jonnym1ller
−7.9%
since Sep 30
The idea
I believe bioelectric signaling, the control layer behind regeneration and tissue repair, is heading toward real commercial medicine, especially as frontier AI gets applied to the biology. Since the direct pioneers are private, this basket owns the public stack around them: profitable devices and tools leaders as ballast, regenerative-medicine pure-plays, and AI-biology platforms, sized so the smaller bets stay asymmetric rather than concentrated.
What it owns
- Companies already treating disease by stimulating electrical signals in the nervous system, demonstrating the commercial viability of bioelectric intervention. · MedtronicAlready builds and scales electrical stimulation devices for spinal cord and brain, the largest existing commercial franchise built on treating the body with electrical signals., Boston ScientificRepeatedly acquires and scales electrical-intervention businesses across cardiac rhythm and nerve stimulation, positioned as the most likely acquirer to bring bioelectric science into clinical practice., Inspire Medical SystemsBuilt a commercial franchise by stimulating a single nerve to treat sleep apnea, proof that a bioelectric intervention can win patients away from mechanical alternatives., AxogenSells products that help severed peripheral nerves regrow, positioned directly where bioelectric regeneration science would land commercially., NeuroPaceIt reads brain activity and responds with targeted electrical pulses, treating bioelectric signals as an information layer that can be both read and written to clinical effect., LivaNovaStimulates the vagus nerve to treat epilepsy and is expanding into depression, a live test of how far electrical control of the nervous system extends into new indications.31%
- Suppliers of instruments, reagents, and equipment that serve any lab or company pursuing bioelectric science, regardless of which specific approach succeeds. · Thermo Fisher ScientificSells the instruments and reagents that every research lab in this space buys, so it profits from bioelectric progress regardless of which specific approach reaches patients., DanaherSupplies the bioprocessing equipment that manufactures cell therapies and biologics at scale, so any regenerative medicine that reaches patients runs through its systems., Twist BioscienceSells synthetic DNA to researchers doing engineered biology, the raw material for experiments that multiply as AI-designed biology creates new things to build and test., 10x GenomicsMakes tools that map what individual cells are doing, exactly what researchers need to see how bioelectric signals control anatomy at the cellular level.23%
- Platforms using frontier machine learning models to accelerate biological discovery and drug design, the computational tools expected to speed progress in bioelectric medicine. · Recursion PharmaceuticalsThe largest public company focused on applying frontier AI models to drug discovery, the computational approach expected to accelerate bioelectric medicine from lab to clinic., Tempus AIConverts clinical data into training material for AI models, building the infrastructure to carry bioelectric medicine from research into patient care as medicine becomes more model-driven., SchrödingerSimulates molecular physics computationally to replace wet-lab trial and error with predictive models, the same computational shift bioelectric research needs., Ginkgo BioworksPrograms cells at industrial scale, the engineering discipline that bioelectric science implies is possible for controlling biological systems., AbsciUses generative AI to design antibodies from scratch, an asymmetric bet that frontier models can create biology rather than just analyze it.21%
- Businesses selling tissue repair and regeneration products today, the clinical outcome that bioelectric science research is ultimately aimed at enabling. · Krystal BiotechProved that a genetic medicine can be repeatedly dosed to repair skin, showing that regenerative treatments can become durable commercial products rather than one-time cures., VericelMakes money today regrowing cartilage and treating burns with cell-based products, demonstrating the commercial edge of regeneration that bioelectric science would unlock., MiMedx GroupSells placental tissue products that help chronic wounds close, a profitable business in the tissue repair market that bioelectric research would eventually transform., Organogenesis HoldingsOne of the largest sellers of regenerative wound care products, a direct bet that the market for helping the body rebuild tissue keeps growing.18%
- Cash8%